The 85th Scientific Sessions of the American Diabetes Association (ADA 2025)

Replacing diet beverages with water over 18 months leads to greater weight loss, improved glycaemic control, and higher diabetes remission in women with type 2 diabetes (T2D) and overweight or obesity. The benefits were sustained throughout the 18-month trial.

In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).